{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:23Z","timestamp":1761895463716,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.otc.2011.12.013","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T11:30:50Z","timestamp":1333539050000},"page":"471-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chemotherapy:"],"prefix":"10.1016","volume":"45","author":[{"given":"Anna R.","family":"Terry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Central Brain Tumor Registry of the United States. Statistical report: primary brain tumors in the United States, 2004-2006. 2010. Available at: http:\/\/www.cbtrus.org. Accessed January 9, 2010.","key":"10.1016\/j.otc.2011.12.013_bib1"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","article-title":"Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma","volume":"93","author":"Plotkin","year":"2009","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"issue":"2","key":"10.1016\/j.otc.2011.12.013_bib4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.24036","article-title":"Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation","volume":"115","author":"Phi","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib5","first-page":"527","article-title":"Improved preservation of hearing and facial nerve function in vestibular schwannoma via the retrosigmoid approach in a series of 200 patients","volume":"105","author":"Samii","year":"2006","journal-title":"J\u00a0Neurosurg"},{"issue":"3","key":"10.1016\/j.otc.2011.12.013_bib6","first-page":"480","article-title":"Age at symptom onset and long-term survival in patients with neurofibromatosis type 2","volume":"99","author":"Otsuka","year":"2003","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","article-title":"Predictors of the risk of mortality in neurofibromatosis 2","volume":"71","author":"Baser","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.otc.2011.12.013_bib8","first-page":"217","article-title":"Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2","volume":"96","author":"Baser","year":"2002","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0090-3019(96)00487-9","article-title":"A\u00a0comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas","volume":"48","author":"Hamada","year":"1997","journal-title":"Surg Neurol"},{"issue":"16","key":"10.1016\/j.otc.2011.12.013_bib10","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/MAO.0b013e3181b2364c","article-title":"Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium","volume":"30","author":"Fisher","year":"2009","journal-title":"Otol Neurotol"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00129492-200606000-00018","article-title":"The natural history of vestibular schwannoma","volume":"27","author":"Stangerup","year":"2006","journal-title":"Otol Neurotol"},{"issue":"7","key":"10.1016\/j.otc.2011.12.013_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0022215107001077","article-title":"Change in hearing during \u201cwait and scan\u201d management of patients with vestibular schwannoma","volume":"122","author":"Stangerup","year":"2008","journal-title":"J\u00a0Laryngol Otol"},{"issue":"3","key":"10.1016\/j.otc.2011.12.013_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1749-4486.2008.01705.x","article-title":"Conservative management of vestibular schwannomas: third review of a 10-year prospective study","volume":"33","author":"Hajioff","year":"2008","journal-title":"Clin Otolaryngol"},{"issue":"11","key":"10.1016\/j.otc.2011.12.013_bib15","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00005537-200011000-00015","article-title":"Tumor growth and audiometric change in vestibular schwannomas managed conservatively","volume":"110","author":"Massick","year":"2000","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.otc.2011.12.013_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/01.mao.0000185153.54457.16","article-title":"Hearing preservation and facial nerve outcomes in vestibular schwannoma surgery: results using the middle cranial fossa approach","volume":"27","author":"Arts","year":"2006","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.otc.2011.12.013_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00129492-200409000-00027","article-title":"Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects","volume":"25","author":"Slattery","year":"2004","journal-title":"Otol Neurotol"},{"issue":"3","key":"10.1016\/j.otc.2011.12.013_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00005537-200503000-00011","article-title":"Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm","volume":"115","author":"Smouha","year":"2005","journal-title":"Laryngoscope"},{"issue":"8","key":"10.1016\/j.otc.2011.12.013_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/00005537-200308000-00013","article-title":"Surgical excision of acoustic neuroma: patient outcome and provider caseload","volume":"113","author":"Barker","year":"2003","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2005.01.055","article-title":"Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution","volume":"63","author":"Combs","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib21","first-page":"1","article-title":"Results of acoustic neuroma radiosurgery: an analysis of 5 years\u2019 experience using current methods","volume":"94","author":"Flickinger","year":"2001","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2005.036319","article-title":"Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes","volume":"43","author":"Evans","year":"2006","journal-title":"J\u00a0Med Genet"},{"issue":"6429","key":"10.1016\/j.otc.2011.12.013_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane organizing protein causes neurofibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/hmg\/3.1.147","article-title":"The neurofibromatosis gene is inactivated in schwannomas","volume":"3","author":"Twist","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.otc.2011.12.013_bib25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact dependent inhibition of EGFR signaling by NF2\/merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J\u00a0Cell Biol"},{"issue":"5","key":"10.1016\/j.otc.2011.12.013_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00129492-200409000-00024","article-title":"Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas","volume":"25","author":"O\u2019Reilly","year":"2004","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib27","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/onc.2008.427","article-title":"Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas","volume":"28","author":"Lallemand","year":"2009","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib28","first-page":"1493","article-title":"Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation","volume":"23","author":"Fraenzer","year":"2003","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/mao.0b013e31815d4429","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy","volume":"29","author":"Doherty","year":"2008","journal-title":"Otol Neurotol"},{"issue":"13","key":"10.1016\/j.otc.2011.12.013_bib30","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/0008-5472.CAN-07-5849","article-title":"Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma","volume":"68","author":"Ammoun","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.otc.2011.12.013_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4615-0119-0_3","article-title":"The role of neuropilin in vascular and tumor biology","volume":"515","author":"Klagsbrun","year":"2002","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","article-title":"VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate","volume":"26","author":"Cay\u00e9-Thomasen","year":"2005","journal-title":"Otol Neurotol"},{"issue":"3","key":"10.1016\/j.otc.2011.12.013_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11060-007-9336-0","article-title":"Expression of VEGF and its receptor genes in intracranial schwannomas","volume":"83","author":"Uesaka","year":"2007","journal-title":"J\u00a0Neurooncol"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.otc.2011.12.013_bib35","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","article-title":"Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors","volume":"70","author":"Wong","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","article-title":"Using audiometric thresholds and word recognition in a treatment study","volume":"27","author":"Halpin","year":"2006","journal-title":"Otol Neurotol"},{"issue":"3","key":"10.1016\/j.otc.2011.12.013_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0194-5998(95)70101-X","article-title":"Committee on Hearing and Equilibrium Guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc","volume":"113","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/000348948809700110","article-title":"Hearing preservation in unilateral acoustic neuroma surgery","volume":"97","author":"Gardner","year":"1988","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"11","key":"10.1016\/j.otc.2011.12.013_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/000348940311201111","article-title":"Histopathology of the inner ear in unoperated acoustic neuroma","volume":"112","author":"Mahmud","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/WCO.0b013e328318402a","article-title":"Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas","volume":"21","author":"Gerstner","year":"2008","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.otc.2011.12.013_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.otc.2011.12.013_bib42","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase\u00a0II\u00a0studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib43","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1227\/01.NEU.0000316858.25606.8F","article-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II","volume":"62","author":"Harris","year":"2008","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.otc.2011.12.013_bib44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1215\/15228517-2007-062","article-title":"Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas","volume":"10","author":"Lamborn","year":"2008","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.otc.2011.12.013_bib45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1365-2273.2001.00490.x","article-title":"Guidelines for the grading of tinnitus severity: the results of a working group commissioned by the British Association of Otolaryngologists, Head and Neck Surgeons","volume":"26","author":"McCombe","year":"2001","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/00016486709128769","article-title":"Meni\u00e9re\u2019s disease and hydrochlorothiazide: a critical analysis of symptoms and therapeutic effects","volume":"63","author":"Klockhoff","year":"1967","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1044\/jshr.3401.197","article-title":"Tinnitus reaction questionnaire: psychometric properties of a measure of distress associated with tinnitus","volume":"34","author":"Wilson","year":"1991","journal-title":"J\u00a0Speech Hear Res"},{"issue":"2","key":"10.1016\/j.otc.2011.12.013_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/019459988509300202","article-title":"Facial nerve grading system","volume":"93","author":"House","year":"1985","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/019459988809800401","article-title":"Chemotherapy of bilateral acoustic neuromas","volume":"98","author":"Jahrsdoerfer","year":"1988","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.otc.2011.12.013_bib50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1215\/15228517-2008-021","article-title":"Neurooncology clinical trial design for targeted therapies: lesions learned from the North American Brain Tumor Consortium","volume":"10","author":"Chang","year":"2008","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.mao.0000180484.24242.54","article-title":"The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level","volume":"27","author":"Neff","year":"2006","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.otc.2011.12.013_bib52","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study","volume":"29","author":"Clark","year":"2008","journal-title":"Otol Neurotol"},{"issue":"7","key":"10.1016\/j.otc.2011.12.013_bib53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"issue":"5706","key":"10.1016\/j.otc.2011.12.013_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.otc.2011.12.013_bib56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16","author":"Besse","year":"2010","journal-title":"Clin Cancer Res"},{"unstructured":"Clinical trial description. PTC299 for treatment of neurofibromatosis type 2. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00911248?term=ptc299&rank=1. Accessed January 9, 2010.","key":"10.1016\/j.otc.2011.12.013_bib57"},{"unstructured":"Clinical trial description. Lapatinib study for children and adults with neurofibromatosis type 2 (NF2) and NF2-related tumors. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00973739?term=lapatinib+vestibular+schwannoma&rank=2. Accessed January 9, 2010.","key":"10.1016\/j.otc.2011.12.013_bib58"},{"issue":"8","key":"10.1016\/j.otc.2011.12.013_bib59","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.otc.2011.12.013_bib60","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate)","volume":"69","author":"Mukherjee","year":"2009","journal-title":"Cancer Res"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666511002350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666511002350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:50:42Z","timestamp":1758466242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666511002350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0030666511002350"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2011.12.013","relation":{},"ISSN":["0030-6665"],"issn-type":[{"type":"print","value":"0030-6665"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy:","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2011.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}